Progressive dosing helps you meet individual patient needs. With REQUIP, you have the flexibility to increase your patient’s total daily dose as needed, to a maximum total daily dose of 24 mg/day.10 In pooled clinical trials, at least 75% of responders achieved an initial response up to 9 mg/day.11 Initial response was defined as a 30% reduction in UPDRS motor score from baseline.11 Titrate REQUIP (up to 24 mg/day) to achieve maximum therapeutic response in your patients.
REQUIP Provides Progressive Dosing for a Progressive Disease
Titrate REQUIP to achieve maximum therapeutic response (up to 24 mg/day) based on patient needs.
* The Sample Kit for REQUIP provides dosing up to 9 mg/day. After week 8, if necessary, the total daily dose may be increased by up to 3 mg/day weekly to a total dose of 24 mg/day.
Dosage should be increased to achieve a maximum therapeutic effect, balanced against principal side effects.
Color-coded Tiltab® Tablets clearly identify different dosage strengths and facilitate easy handling.
Progressive dosing helps you meet individual patient needs.11
Dosage should be increased to achieve a maximum therapeutic effect, balanced against principal side effects
With REQUIP, you have the flexibility to increase your patient’s total daily dose as needed, to a maximum total daily dose of 24 mg
† Initial response was defined as a 30% reduction in UPDRS motor score from baseline.
‡Analysis of pooled data from 3 clinical trials at 6 months in patients with early PD (Hoehn & Yahr stage I-III) receiving monotherapy with REQUIP (N=463).
§ The average daily dose was: at 6 months, 10.1 ± 5.8 mg of ropinirole and at 5 years, 16.5 ± 6.6 mg of ropinirole (plus 427 ± 221 mg of open-label
There is an 8-week Sample Kit available that can conveniently titrate patients over an 8-week period.
Download a Pocket Dosing Card for REQUIP.
ADDITIONAL SAFETY AND DOSING INFORMATION
NOT A CONTROLLED SUBSTANCE
- REQUIP is not a scheduled medication
DOSING CONSIDERATIONS
- REQUIP is metabolized by the liver
- Hepatically impaired patients may have higher plasma levels and lower clearance of the drug. Therefore, the drug should be titrated with caution in this population
- Dosage adjustment may be required if REQUIP is used with estrogen or CYP450 1A2 inhibitors, such as ciprofloxacin
- No dosage adjustment is necessary for patients with mild-to-moderate renal impairment (creatinine clearance 30 to 50 mL/min). REQUIP has not been studied in patients with severe renal impairment
